About U3 small nucleolar RNA-interacting protein 2
U3 small nucleolar RNA-interacting protein 2 (RRP9) is a protein
from Homo sapiens identified by UniProt accession
O43818, 475 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | U3 small nucleolar RNA-interacting protein 2 |
| UniProt accession | O43818 |
| Gene | RRP9 |
| Organism | Homo sapiens |
| Length | 475 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (10)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.49
- neoplasm · score 0.09
- pachyonychia congenita · score 0.07
- cancer · score 0.02
- Keloid · score 0.02
- pancreatic neoplasm · score 0.01
- colorectal neoplasm · score 0.01
- hepatocellular carcinoma · score 0.00
- orthostatic intolerance · score 0.00
- major depressive disorder · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43818-F1 | alphafold | PREDICTED | 83.41 | — |
Amino-acid sequence (475 residues)
MSATAAARKR GKPASGAGAG AGAGKRRRKA DSAGDRGKSK GGGKMNEEIS SDSESESLAP RKPEEEEEEE LEETAQEKKL RLAKLYLEQL RQQEEEKAEA RAFEEDQVAG RLKEDVLEQR GRLQKLVAKE IQAPASADIR VLRGHQLSIT CLVVTPDDSA IFSAAKDCSI IKWSVESGRK LHVIPRAKKG AEGKPPGHSS HVLCMAISSD GKYLASGDRS KLILIWEAQS CQHLYTFTGH RDAVSGLAFR RGTHQLYSTS HDRSVKVWNV AENSYVETLF GHQDAVAALD ALSRECCVTA GGRDGTVRVW KIPEESQLVF YGHQGSIDCI HLINEEHMVS GADDGSVALW GLSKKRPLAL QREAHGLRGE PGLEQPFWIS SVAALLNTDL VATGSHSSCV RLWQCGEGFR QLDLLCDIPL VGFINSLKFS SSGDFLVAGV GQEHRLGRWW RIKEARNSVC IIPLRRVPVP PAAGS
Explore U3 small nucleolar RNA-interacting protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets